Novavax, Inc. (NVAX) - NASDAQ
  • Jun. 4, 2013, 7:52 AM

    Novavax (NVAX) makes a public offer to acquire all outstanding shares of Isconova, a Sweden-based company which makes vaccine adjuvants and has an impressive list of big pharma partners. The all-stock deal is worth~$29.6M. (PR)

    | Jun. 4, 2013, 7:52 AM
Company Description
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus... More
Sector: Healthcare
Industry: Biotechnology
Country: United States